MESA LABORATORIES INC /CO/

Mesa Laboratories Inc. filed its annual report on Form 10-K, detailing its business operations across four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The report highlights the recent acquisition of GKE, which has been integrated into the Sterilization and Disinfection Control division. The company also provided updates on its backlog, customer concentration, and human capital, noting a decrease in backlog and a stable employee headcount with reduced turnover.

Mesa Laboratories reported mixed results for its fourth fiscal quarter and full fiscal year 2026. For Q4, revenues increased 2.6% to $63.7 million, while the company posted a GAAP net loss of $4.1 million. Full fiscal year 2026 revenues grew 3.4% to $249.1 million, with GAAP net income of $6.7 million. The company also repaid $14.7 million in debt during Q4, reducing its net leverage ratio to 2.11, and expects overall revenues to return to positive core organic growth in 1Q27.

Mesa Laboratories reported a 3.4% increase in full fiscal year 2026 revenues to $249.1 million and a 13.3% rise in operating income to $18.5 million. For the fourth quarter of fiscal year 2026, revenues grew 2.6% to $63.7 million and operating income surged 87% to $2.7 million. The company repaid $14.7 million of debt in 4Q26, reducing its Total Net Leverage Ratio to 2.11. Challenges in the Biopharmaceutical Development division due to commercial execution and export controls were noted, while the Sterilization and Disinfection Control division showed strong growth.

Mesa Laboratories, Inc. announced that it will release its financial results for the fourth quarter and the fiscal year ended March 31, 2026. The press release is scheduled for Wednesday, May 27, 2026, at approximately 6:00 A.M. Eastern Time.